An FDA warning letter for unapproved drug claims on cosmetic products is far more likely to come from one of the agency’s district offices in 2016 versus years past, but recipients should treat such warnings with no less gravity than those that issue from the Center for Food Safety and Applied Nutrition’s headquarters.
In an Oct. 3 email, Marianna Naum, who handles strategic communications and public engagement within FDA’s Office of Foods and...





